Lexaria Bioscience Corp. (Nasdaq: LEXX) announced that it will implement a 1-for-15 reverse stock split of its common stock, effective 12:01 a.m. EST on August 3, 2026. The move is primarily intended to raise the per-share market price to regain compliance with Nasdaq's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). The company also aims to stabilize uncertain stock conditions amid critical business drivers that it believes are in the best interests of shareholders.
Richard Christopher, CEO of Lexaria, emphasized the strategic importance of the reverse split for maintaining the company's Nasdaq listing. "The Reverse Split is a critical step towards our continued listing on Nasdaq," he stated. Christopher noted that Nasdaq compliance is vital for attracting new business development partners, advancing existing discussions, and broadening investor appeal. He added that recent equity market weakness contradicts the potential of the company's technology, necessitating a stable foundation to capitalize on opportunities.
The reverse split will consolidate the current issued share capital of 24,787,446 shares into approximately 1,652,518 shares, with fractional shares rounded up to the nearest whole number. The number of authorized shares will also be reduced from 220,000,000 to 14,666,667, and the exercise prices of outstanding convertible securities, such as options and warrants, will be adjusted accordingly. The company determined the 1-for-15 ratio after examining 24 reverse stock splits by Nasdaq-listed biotech firms from January 1 to June 30, 2026, which had an average ratio of 1-for-18.
Lexaria plans to proactively request a Nasdaq hearing to appeal any potential delisting notification, expecting to meet the minimum bid price requirement by mid-August before any hearing occurs. Following the reverse split, shares will continue trading under the symbol LEXX with a new CUSIP number 52886N604. Shareholders holding physical certificates must contact Computershare Trust Company of Canada for procedures. The company's DehydraTECH drug delivery platform, protected by 66 patents, aims to improve drug absorption and reduce side effects, with applications across various therapies.
While the reverse split is a common strategy for companies facing delisting, it does not change the fundamental value of the company. However, for Lexaria, maintaining Nasdaq listing is crucial for credibility and access to capital markets. The move reflects the company's commitment to addressing compliance issues and positioning itself for future growth, as highlighted by Christopher's emphasis on the importance of a stable stock price for business development and investor confidence.
